Prognostic Value of KRAS Mutations in Stage III Colon Cancer: Post-Hoc Analyses of the Petacc8 Phase III Trial
نویسندگان
چکیده
منابع مشابه
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
BACKGROUND The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III trial. PATIENTS AND METHODS We analyzed the prognostic impact of KRAS exon 2 mutations in stage III colon cancer patients (n = 1657) receiving adjuvant FOLFOX ± cetuximab therapy included in the PETACC8 trial. Patients with BRAF-m...
متن کاملPrognostic Value of Lymph Node Ratio in comparison to Lymph Node Metastases in Stage III Colon Cancer
Background & Objectives: Colon cancer is currently of high incidence and mortality rate. Identifying the factors influencing its prognosis can be very beneficial to its clinical treatment. Recent studies have shown that lymph nodes ratio can be considered as an important prognostic factor. The aim of the present study is to investigate the effect of this factor on the prognosis of the ...
متن کاملprognostic value of lymph node ratio in comparison to lymph node metastases in stage iii colon cancer
background & objectives: colon cancer is currently of high incidence and mortality rate. identifying the factors influencing its prognosis can be very beneficial to its clinical treatment. recent studies have shown that lymph nodes ratio can be considered as an important prognostic factor. the aim of the present study is to investigate the effect of this factor on the prognosis of the patie...
متن کاملPredictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
BACKGROUND Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer. METHODS We examined associations of PIK3CA oncogene mutation with relapse, survival, and treatment efficacy in 627 stage III colon carcinoma ca...
متن کاملS-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
BACKGROUND S-1 is an oral fluoropyrimidine whose antitumor effects have been demonstrated in treating various gastrointestinal cancers, including metastatic colon cancer, when administered as monotherapy or in combination chemotherapy. We conducted a randomized phase III study investigating the efficacy of S-1 as adjuvant chemotherapy for colon cancer by evaluating its noninferiority to tegafur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu193.24